Shares of Quest Diagnostics rose mid-day after New York State’s Clinical Laboratory Evaluation Program (CLEP) granted approval for the company’s Haystack MRD test, pushing the stock higher by roughly 2.5% in mid-session trading.
The Haystack MRD assay is a circulating tumor DNA liquid biopsy intended to detect residual or recurrent disease in patients with solid tumor cancers. With CLEP approval, the test is now available for clinician ordering across all 50 U.S. states. New York’s approval is notable because the state operates one of the most rigorous clinical laboratory oversight programs in the nation, which requires a formal technical review before laboratory-developed tests may be offered to patients there. Clearing that process removes a regulatory barrier that had prevented full nationwide availability until now.
Prior to this clearance, clinicians had access to the Haystack MRD test in 49 states plus the District of Columbia since late 2024. The product also holds FDA Breakthrough Device Designation specifically for identifying minimal residual disease in stage II colorectal cancer patients. That designation highlights the clinical importance of the test within that specific indication.
Support for the test’s clinical credibility was underlined by its study results in investigational settings, including work published in The New England Journal of Medicine, demonstrating utility in landmark research. Such published evidence has been cited alongside the regulatory milestones as validating the test’s role in post-treatment surveillance for some cancer patients.
The timing of the approval coincided with a broader market backdrop that was constructive for defensive and healthcare names. On the session in question, the S&P 500 gained 0.77% while the Dow Jones Industrial Average rose 1.1%. That followed a sharp selloff the prior day when the S&P 500 fell 1.4% and the Nasdaq dropped 2.2% amid investor concerns about returns on AI-related capital spending. As capital rotated away from technology and semiconductor stocks, healthcare and defensive sectors benefited from inflows, providing an additional tailwind for Quest Diagnostics shares.
On the trading day described, Quest Diagnostics shares were quoted at $202.19, positioning the stock above its 52-week low of $164.65 and below its 52-week high of $213.50. The completion of the Haystack MRD nationwide rollout, coupled with the sector rotation, helped push the shares toward the upper end of their recent trading range.
Context and implications
- The New York CLEP approval removes a previously unresolved regulatory requirement that limited availability of the Haystack MRD test in one state known for strict laboratory oversight.
- The test’s Breakthrough Device Designation is specific to the identification of minimal residual disease in stage II colorectal cancer patients.
- Market dynamics that favored healthcare and defensive stocks on the day reinforced the impact of the company-specific regulatory news on Quest Diagnostics’ share price.
Where information is limited, the article reflects only the approvals, availability, regulatory context, published investigational support, and market moves explicitly stated.